医疗器械公司ImpediMed（ASX： IPD）Q3财季营收与ARR创新高 股价回探低位后放量反弹

( 图片来源：《澳华财经在线》) 

医疗器械公司ImpediMed（ASX: IPD）Q3财季营收与ARR创新高 股价回探低位后放量反弹  

澳大利亚医疗科技公司 ImpediMed Limited（ASX: IPD）日前公布2025财年第三季度（截至3月31日）财报。报告显示，公司在季度收入、客户回款、合同总值（TCV）及年度经常性收入（ARR）等核心指标上全面刷新历史纪录，SOZO®数字健康平台在美国市场的商业化持续提速。

■ 财务表现创新高，续签提价提升收入质量

第三财季公司实现收入 340万澳元，同比增长28%；客户现金回款达到 410万澳元，创下季度新高；核心业务ARR升至 1,370万澳元，环比增长10%，同比增长27%。

期内新签与续签合同总值（TCV）达 490万澳元，环比大增53%。公司指出，续签合同平均价格提升 19%，涵盖多家美国重点医疗客户，包括NCCN癌症中心及大型整合医疗网络（IDNs）。截至季度末，公司现金余额为 2,790万澳元，足以覆盖8.1个季度运营支出。

■ 销售转化提速 临床拓展稳步推进

得益于市场宣传与行业活动（包括首次参与ONS肿瘤护理大会），公司本季度识别新增销售线索超过 500 条，创历史新高。新任销售高级副总裁 Scott Long 已全面接手销售团队，重点推进线索转化与在 **28家已签署主服务协议（MSA）**的美国IDN医疗网络中的设备部署。

同时，公司旗下 SOZO Pro 设备正针对心衰等新适应症开展临床试点研究，进一步拓展平台在慢性病管理中的应用边界。

■ 供应链提前布局 股价回升引关注

为应对潜在关税与元器件短缺风险，公司计划于第四季度一次性支付约 120万澳元，提前采购关键电子组件。全年运营支出预计将较上年下降约10%，成本控制策略持续推进。

二级市场方面，公司股价于今年4月中旬再次回探 0.03澳元——该价位为2020年形成的历史低点区域。此后，股价在放量配合下出现反弹，盘中一度触及 0.042澳元，上周五收于 0.039澳元。

成交量同步放大，引发市场关注该价位是否有望再次构筑中期技术支撑，并推动股价重拾升势。

■ 展望焦点：基本面改善是否引发估值重估

展望后市，以下几项关键变量值得关注：

——ARR 持续增长与续签提价带来的收入质量提升；

——充足现金储备下的市场扩张节奏；

——美国市场销售转化效率；

——SOZO Pro 临床拓展进展，特别是心衰等新适应症的验证；

——经营改善与技术面修复能否共振，带动市场对公司估值的重估预期。

ImpediMed (ASX: IPD) Reports Record Q3 Performance; Commercial Momentum Builds and Shares Rebound 

5 May 2025 | ACB News – Sydney，ImpediMed Limited (ASX: IPD), a leading Australian medical technology company, has reported record results for the third quarter of FY2025, ended 31 March. Key financial metrics reached new highs as the company continues to scale deployment of its SOZO® digital health platform in the U.S.

■ Record Revenue, Growing Recurring Income, and Strengthened Customer Base

Q3 revenue rose to A$3.4 million, up 28% year-on-year, with record customer receipts of A$4.1 million. Core Annual Recurring Revenue (ARR) reached A$13.7 million, up 10% from the previous quarter and 27% from a year earlier.

Total Contracted Value (TCV) signed in the quarter was A$4.9 million, a 53% increase from Q2. The company noted a 19% average price uplift on contract renewals, including across NCCN centers and large integrated delivery networks (IDNs) in the U.S. ImpediMed’s cash balance stood at A$27.9 million, equivalent to 8.1 quarters of operating runway, following a US$10 million drawdown from its US$15 million growth facility.

■ Sales Acceleration and Clinical Expansion

ImpediMed identified over 500 new sales leads during the quarter—a record for the company—driven by increased marketing and conference engagement, including its debut at the Oncology Nursing Society (ONS) annual meeting. With new SVP of Sales Scott Long now leading the team, focus has shifted to conversion and scaling deployments across 28 U.S. IDNs with existing MSAs.

Meanwhile, the SOZO Pro device is undergoing clinical trials in heart failure and other new indications. The platform remains the only FDA-cleared BIS-based system included in NCCN guidelines for lymphoedema screening.

■ Supply Chain Strategy and Share Price Rebound

To ensure supply continuity, ImpediMed will make a one-time payment of A$1.2 million in Q4 to procure critical components at pre-tariff prices. FY25 operating costs are projected to be 10% lower than FY24, reflecting ongoing cost discipline.

On the market front, shares rebounded last week after retesting the A$0.03 level, a key low first established in 2020, reaching an intraday high of A$0.042 on increased trading volume. Investors are watching to see whether the price base can support a sustained recovery.

■ Outlook: Fundamentals Align with Market Interest

Looking ahead, several factors may influence valuation:

Continued ARR growth and renewal pricing gains

Execution of U.S. commercial rollout

Clinical progress in heart failure and other indications

Strong cash position supporting expansion

A potential re-rating if operational progress and share price recovery converge

【异动股】锂矿股Jindalee Lithium (ASX:JLL)单周暴涨135%：McDermitt项目获美国FAST-41计划认可  

Jindalee Lithium Ltd (ASX股票代码:JLL)股价异动，上周三飙涨37.81%。

澳华财经在线数据库显示，JLL最新价0.565澳元，已发行股本7359万股，市值4158万澳元。截止一季度末，公司账面现金结余374万澳元。

Jindalee旗舰资产McDermitt锂项目近日获得美国《修复美国地面运输法案》(FAST-41)下的“透明项目”资格认定，目前全美仅10个资源项目获得该资质。

Jindalee首席执行官lan Rodger表示，被列入前十个FAST-41透明项目证明McDermitt对美国矿产安全的战略重要性，将有助于其勘探运营计划（EPO）在审批上获得更大透明度和更多联邦政府支持。

过去一周JLL澳交所股价上扬135.42%。

（图片来源：JLL公告）

（图片来源：JLL公告）

【异动股】营养保健品公司Nuchev (ASX:NUC)前三季度营收翻倍增长 

Nuchev Ltd (ASX股票代码:NUC)股价异动，上周三飙涨18.75%。

澳华财经在线数据库显示，NUC最新价0.19澳元，已发行股本1.46亿股，市值2780万澳元。截止一季度末，公司账面现金结余382万澳元。

最新季报显示，本财年前三季度Nuchev集团营收达1690万澳元，同比增99%，其中新收购的保健品药房渠道业务bWellness贡献大部分增长。

Oli6 营养品业务保持积极增长，据Iqvia Scan统计第三季度Oli6澳新本地销售额增长20%（MAT），远超过仅增长1%的婴儿配方奶粉整体市场增长。

当季Oli6中国跨境电商渠道销售额达140万澳元，同比增106%。

Nuchev首席执行官Mick Myers表示，公司当前战略重点之一是扩大市场份额，力求在澳新、中国和东南亚地区实现更大销售规模和渠道的多样化。

（图片来源：NUC公告）

（图片来源：NUC公告）

股价单日飙升近1倍！Andromeda突破性生产4N级高纯氧化铝（HPA）Great White项目再迎估值催化  

ACB News《澳华财经在线》2025年5月1日讯（编辑:Anna ）: 澳交所高岭土开发商Andromeda Metals Ltd（ASX: ADN）今日宣布，其实验室规模试验成功生产出纯度高达99.9985%的4N级高纯氧化铝（HPA），标志着其自主研发的创新工艺流程取得重大突破。该工艺以Great White项目出产的精炼高岭土为原料，具显著成本和碳减排优势，有望拓展公司高附加值产品线。详见《【异动股】Andromeda Metals (ASX:ADN)股价高飙：The Great White高岭土项目临近最终投资决议》

公司指出，新HPA工艺完全不依赖传统高成本的铝金属为原料，也无需使用高温高压下的酸性重结晶程序，预计最多可减少68%的碳排放，同时大幅降低能源与资金成本。

此次HPA样品由美国权威机构EAG Eurofins与澳大利亚CSIRO独立分析，确认产品纯度达4N等级的99.9985%，远高于3N等级（99.9%）市场门槛，显示出极高产品竞争力。HPA是LED、半导体、锂电池和陶瓷等高端领域的核心材料，市场研究机构预测，至2028年全球HPA需求将超过供应45%。

市场强烈响应，股价日内飙涨逾90%，本周已翻两倍

受利好消息刺激，今日市场对Andromeda的回应极为积极。截至澳洲东部时间上午10:48，Andromeda股价大幅飙升92.86%，至0.027澳元，成交量高达4758万股，交易金额近百万澳元。Andromeda股价累计放量上涨已达2倍，今日盘中股价创出52周新高——快速放大的成交量和飙升的股价，似乎在表明资金对其技术突破及未来估值潜力的追捧。

延伸背景：Great White项目临近最终投资决策，HPA突破带来新增长引擎

《澳华财经在线》上周曾报道，Andromeda的旗舰项目Great White已接近最终投资决策阶段（FID），目前正与主要承包商就工程设计与建设预算进行谈判，并计划于年中前后完成融资安排。该项目拥有世界级高岭土资源，并被南澳政府列为关键矿产项目。

而此次HPA技术的成功突破，正是基于Great White项目高品质精炼高岭土，凸显项目的多元价值潜力。尽管公司强调短期重点仍在推动Great White高岭土产品商业化，但HPA发展路径已被明确纳入未来战略重点。

临时首席执行官Sarah Clarke表示：“我们非常高兴看到，自主研发的HPA工艺成功地将Great White高岭土转化为超高纯度产品。这不仅增强了公司创新能力，也为未来开拓高附加值材料市场奠定了坚实基础。”

公司下一步计划启动HPA项目的范围研究（Scoping Study），并与潜在客户就产品规格和合作机制展开沟通，同时探索政府资助计划，以支持新材料产业化发展。

Andromeda Metals Ltd (ASX: ADN) 4N HPA Breakthrough Sparks Share Price Surge to 52-Week High, Unlocking New Growth Opportunities 

May 1, 2025 | ACB News — Reporter: Anna

ASX-listed kaolin developer Andromeda Metals Ltd (ASX: ADN) today announced a major technical breakthrough in its High-Purity Alumina (HPA) development efforts. The company has successfully produced 4N-grade (99.9985% purity) HPA at laboratory scale, using a proprietary process based on refined kaolin from its flagship Great White Project in South Australia.

The novel process, developed in-house by Andromeda, eliminates the need for traditional high-cost aluminium feedstocks and avoids high-temperature, high-pressure acid re-crystallisation steps. The company estimates up to 68% lower carbon emissions compared to conventional methods, with significantly reduced energy and capital costs.

HPA samples were independently tested by EAG Eurofins in the U.S. and CSIRO in Australia, confirming 4N-level purity, well above the 3N (99.9%) commercial benchmark. HPA is a critical input for LED, semiconductor, ceramic, and lithium-ion battery technologies. Market forecasts anticipate global HPA demand to outpace supply by 45% by 2028, driving strong pricing momentum.

Market Responds Sharply: Share Price Hits 52-Week High

Investors have responded enthusiastically to the announcement. By 10:48 am AEST, Andromeda’s share price surged 92.86% to $0.027, with trading volume exceeding 47.58 million shares, totalling nearly A$1 million in turnover. The stock has more than doubled this week on surging volume, with intraday prices hitting a 52-week high—a strong indication of growing investor appetite for Andromeda’s technological advancement and future valuation upside.

Strategic Context: HPA Adds Value to Great White Ahead of Final Investment Decision

Last week, ACB News reported that Andromeda is approaching a Final Investment Decision (FID) for its Great White Project, currently in advanced discussions with key engineering partners and financiers. The South Australian government has designated Great White a strategic critical minerals project.

While Andromeda remains focused on commercialising its premium kaolin products in the near term, this HPA breakthrough significantly expands the project’s long-term value proposition. The HPA process leverages Great White’s ultra-pure kaolin feedstock, strengthening Andromeda’s potential entry into high-value downstream materials.

Acting CEO Sarah Clarke commented:

"We’re delighted to confirm that our internally developed process can transform Great White kaolin into ultra-high-purity HPA. This positions us strongly for future participation in the energy transition and advanced materials supply chains."

The company will now advance to a Scoping Study for its HPA pathway and engage with potential offtake partners and government funding programs to accelerate commercialisation.

免责声明：市场有风险投资需谨慎！本网所发所有文章，包括本网原创、编译及转发的第三方稿件及评论，均不构成任何投资建议，交易操作或投资决定请询问专业人士。

(郑重声明：ACB News《澳华财经在线》对标注为原创的文章保留全部著作权限。澳大利亚境内任何媒体、企业网站或App的任何形式转载前，必须获得本网授权或经相关安排，转载事宜请邮件联系本网。未经本网授权或书面同意的转载——无论直接转载或通过第三方转载，均视为侵权！侵权必究！)

更多资讯

1 锂矿股Jindalee Lithium (ASX:JLL)单周暴涨135%：McDermitt项目获美国FAST-41计划认可

2 【异动股】Andromeda Metals (ASX:ADN)股价高飙：The Great White高岭土项目临近最终投资决议

3 【异动股】中国限制对美钪产品出口Sunrise Energy Metals (ASX:SRL)股价接连飙升

4 【异动股】Cyprium Metals (ASX:CYM)完全控股西澳2000平方公里Paterson铜矿勘探项目

5 【异动股】Aspire Mining (ASX:AKM)世界级“肥煤”炼焦煤项目预计二季度投建

6 【异动股】紫金矿业战略入股澳交所上市金矿公司Strickland Metals (ASX:STK)